CytoRecovery — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

CytoRecovery is a private, early-revenue stage company providing innovative tools for the cell therapy and life sciences research markets. Its core technology, the CytoR1 Platform, offers a gentle, label-free method for sorting phenotypically similar cells, addressing a key bottleneck in cell processing workflows. The company has begun commercializing its platform and associated reagents, targeting academic, biotech, and pharmaceutical researchers. Its recent feature in an NIH technology showcase and publication of application notes indicate growing visibility and validation within the scientific community.

Cell TherapyRegenerative Medicine

Technology Platform

Proprietary label-free cell sorting platform (CytoR1) based on dielectrophoresis (DEP) technology for gentle separation and enrichment of live cell populations without antibodies or labels.

Opportunities

The growing cell therapy and regenerative medicine markets create strong demand for gentle, label-free cell processing tools to improve cell viability and function.

The technology's applicability in dissecting the tumor microenvironment and sorting immune cells aligns with major research and therapeutic trends.

Potential for integration into GMP manufacturing workflows for cell therapies represents a significant long-term opportunity.

Risk Factors

Facing intense competition from established, well-funded giants in the cell sorting market (e.g., BD, Miltenyi).

Risk of slow adoption as researchers may be hesitant to change from proven FACS/MACS methods.

As a private, early-revenue company, financial sustainability and the ability to scale manufacturing and sales are key uncertainties.

Competitive Landscape

CytoRecovery competes in the cell separation market dominated by fluorescence-activated cell sorters (FACS, e.g., BD Biosciences) and magnetic-activated cell sorting (MACS, e.g., Miltenyi Biotec, STEMCELL Technologies). Its differentiation is a label-free, gentle approach based on dielectrophoresis, contrasting with label-dependent or higher-shear methods. Other niche players may offer microfluidic or acoustic sorting technologies, making the landscape for advanced sorting tools increasingly crowded.

More companies in United States →